Mayo Clinic Arizona
GI medical oncologist, interests in early phase therapeutics and drug development
Talks (70)
Air Time: 484:40:20
ODAC evaluation of PFS IN CODEBREAK200
Dec 29
Tofacitinib in refractory ICI hepatitis
Dec 27
BMS acquires Rayzebio
Dec 26
KN 585 now published
Dec 20
Belzutifan approved for RCC
Dec 15
FDA approval of enfortumab/pembro for UC
Dec 15
Nirogacestat FDA approval
Nov 30
FDA approves pembro based off KN689
Nov 29
Fruquintinib FDA approved for mCRC
Nov 09
PANIRINOX study negative
Nov 01
Amivantamab in the PAPILLON study
Oct 31
FDA approves toripalimab
Oct 30
Updated results from KN811
Oct 30
FDA approval of pembrolizumab from KN671
Oct 17
KEYNOTE 671 meets OS co-primary endpoint
Oct 10
MRD testing in ESCC
Oct 01
anti TIGIT mAb +/- atezolizumab
Oct 01
Tucatinib + trastuzumab in HER-2 BTC
Oct 01
MARIPOSA trial positive
Sep 28
Bosutinib approval for Pediatric Ph+ CML
Sep 27
NCCN guideline updates for CRC
Sep 25
LEAP-006 and 008 negative in NSCLC
Sep 22
GALAXY trial and ctDNA/MRD
Sep 19
MRD in stage 2 colon cancer
Sep 07
COBRA/NRG-005 closed early
Sep 01
Enhertu gets breakthrough designation
Aug 31
Luspatercept approval in MDS
Aug 30
trastuzumab with ram/taxol in GEJ cancer
Aug 29
Divarasib in solid tumors
Aug 24
CABINET trial positive
Aug 24
FDA approval of TAS-102/bev in mCRC
Aug 20
Melphalan in uveal melanoma
Aug 20
Incidences of HCC in the US
Jul 31
How do I approach treating rectal cancer
Jul 31
liver transplantation for mCRC
Jul 31
anti-EGFR + TAS-102 in mCRC
Jul 30
RWE for atezo/bev in HCC
Jul 27
CARES 310 clinical trial in HCC
Jul 26
OS results from IMPOWER 010
Jul 20
Cldn18.2 a new target for GEJ cancers?
Jul 12
Abscopal effect from radiation and ICI?
Jul 12
KEYNOTE 0811 only beneficial for PD-L1+?
Jun 27
KEYNOTE 585 press release
Jun 23
PARADIGM biomarker trial findings
Jun 09
How to approach treating rectal cancer
Jun 09
